How many sources does BPC-157 have?
A long bibliography can return to the same experiment. Follow BPC-157 through the original tests and the recurring names in their author lists.
Rat tendon-cell receptor experiment
The experiment starts with cells from a rat Achilles tendon. Expose them to BPC-157 and they make more growth-hormone receptors; add growth hormone, and cell proliferation increases. The 2014 tendon-cell paper reports receptor expression rising up to sevenfold.
I trust a receptor count more readily than a repair slogan. A receptor is a place on a cell where a signal can be received. Counting more of those places gives the authors something concrete to investigate, with the species and the laboratory conditions still attached. “Repair peptide” loses the assay’s useful specificity.
That is one identifiable source for the much broader growth-hormone claim. A claim about growth hormone can start in a dish of rat cells, travel through reviews, and arrive sounding like a finding about a person's recovery. I retrace that journey to the dish before accepting its human implications.
Where is BPC-157 derived from?
BPC-157 is a synthetic peptide: a short chain of amino acids, the building units of proteins. Its fifteen-unit sequence derives from part of a protein found in human gastric juice. The material used in research is made by chemical synthesis, rather than collected from people's stomachs. The vascular study describes this synthetic gastric peptide.
That distinction clears up a surprisingly persistent ambiguity in the word “source”. There is the biological origin of the sequence, and there is the manufacture of the compound used in an experiment. Gastric origin describes the former. It offers no shortcut to deciding whether a prepared substance is suitable for a person.
The published work reaches far beyond the stomach, including tendons, ligaments, bone and nerves. Those branches are interesting in their own right; the experimental findings remain overwhelmingly preclinical.
Research groups and repeated citations
The bibliography looks broad. Its authorship is much more concentrated: over 80% of published BPC-157 papers came from one laboratory group, a concern discussed in the literature and patent review. A review that retells an experiment expands the discussion without adding another test of that experiment.
The recurring names leave me wanting replication without dismissing the results. The tendon-cell work by Chang and colleagues and the vessel experiments by Hsieh and colleagues also deserve their own space. Treating the entire literature as a single undifferentiated pile loses those distinctions.
I'd put greater confidence in a narrowly specified result repeated by another laboratory. More lists of possible uses would do less for it. The research pages follow the actual experiments; the references retain the full reading list.
Published human observations
A 2025 narrative review identifies three small human reports: knee injections, bladder treatment and intravenous infusion. All were uncontrolled. The reports describe encouraging observations and no reported adverse events, while leaving treatment effects and long-term safety unsettled.
Early inflammatory-bowel-disease development also appears in the literature, under names including PL 14736. Claims of tolerability have circulated without the full trial results needed to examine them closely. An unpublished result leaves a different sort of gap from a published result that disappoints.
The side-effects page separates those human observations from animal protection experiments and community anecdotes. Animal doses and half-life have a separate home because their numbers answer different questions.
FDA status; WADA restrictions
BPC-157 has no FDA approval for treating people. On FDA's page current as of April 22, 2026, it appears among substances whose compounding nominations were withdrawn. Withdrawal confers neither approval nor Category 1 status; FDA's safety concerns remain.
The FDA advisory group discussed BPC-157 in July 2026, with FDA staff advising against adding it to the relevant compounding list. A committee discussion is not a final FDA decision. Compounded medicines remain unapproved by the FDA even when prescribed.
WADA prohibits BPC-157, and the U.S. anti-doping rules apply that prohibition to Olympic and Paralympic athletes. The NFL and UFC also prohibit it. The musculoskeletal narrative review discusses the regulatory and sporting restrictions.